Any current/future new fundraising through debt or equity?

The transcript does not mention any plans for new fundraising through debt or equity in the near future. The company’s cash flow and free cash flow have improved significantly, with free cash flow turning positive in Q3 FY25. Current debt stands at INR 322 crores, down from pre-IPO levels. The company continues to invest in capex, mainly through internal cash flows, with planned capex of INR 175-200 crores annually for the next two years. No explicit mention was made about raising fresh debt or equity for funding these investments. Overall, the focus appears on optimizing existing resources an

Any current/future capex/capital investment/strategic investment?

incurred capex of INR 191 crores in 9 months of FY '25, largely in the CDMO vertical planned capex of INR 175-200 crores annually over next 2 years to commission new plants and production lines INR 32 crores capex over next 2 quarters to upgrade and improve R&D capabilities, focusing on regulated markets and niche dosage forms expanding and increasing manufacturing capabilities for nasal sprays, eye drops, bi-layered tablets, ampoules, FFS small volume parenterals plans to expand into large volume parenterals, dry powder injectable, and lyophilized vials soon expanding/upgrading Mumb

Future growth expectations in sales/revenue/volumes?

CDMO business aims for volume growth of 4%-5% to achieve approx. 12%-13% revenue growth. Historically, the company has achieved 6%-8% volume growth annually, 2-2.5x higher than the market. Recent 12-month trailing volume growth in CDMO is 1.6%, while industry was flat. Q4 and Q1 outlook for CDMO volume growth appears positive with visible order book. New European CDMO contract expected to contribute revenues starting CY 2027, spread evenly over contract length till 2032. API business is rationalizing portfolio, aiming for breakeven in 1 to 2 years. Focus on higher-margin and regulated market p

Future growth expectations in earnings/operating earnings/profits/EPS?

CDMO business volume growth expected at 4-5% in near term, targeting overall revenue growth of 12-13%. European contract (EUR 200 million over duration) to commence commercial supply in 2027, spreading revenues until 2032, providing significant growth. API business is undergoing rationalization; breakeven expected in 1 to 2 years with focus on high-margin, diversified products and regulated market exports. Branded generics and Unosource expected to deliver higher EBITDA margins (18-20%) versus overall CDMO segment (~15.4%). R&D investments continue, INR 94 crores in 9 months FY25 aimed

Current/ Expected Orderbook/ Pending Orders?

The company has visibility on its order book for the next 60 days (Q4 FY25) and expects decent volume growth in this quarter. New contracts discussed earlier are expected to commercialize starting calendar year 2027 (likely Q4 2027 or Q1 next fiscal). The recently signed European contract worth EUR 200 million is expected to commence revenues in CY 2027 and will be spread evenly across years. Management expressed confidence in securing more contracts in Europe over the next 2 to 3 years, following the successful commencement of the first contract. Current order execution for the next six month

IN US

Sale is live|00:00:00left today

Akums Drugs & Pharmaceuticals LtdQ4 FY26Pharmaceuticals & Biotechnology

Akums Drugs & Pharmaceuticals Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹609P/E: 26.6Market Cap: ₹8.6K CrSector: Pharmaceuticals & Biotechnology

Revenue guidance

→CDMO business aims for volume growth of 4%-5% to achieve approx. 12%-13% revenue growth.
→Historically, the company has achieved 6%-8% volume growth annually, 2-2.5x higher than the market.
→Recent 12-month trailing volume growth in CDMO is 1.6%, while industry was flat.
→Q4 and Q1 outlook for CDMO volume growth appears positive with visible order book.
→New European CDMO contract expected to contribute revenues starting CY 2027, spread evenly over contract length till 2032.
→API business is rationalizing portfolio, aiming for breakeven in 1 to 2 years.
→Focus on higher-margin and regulated market products to improve API revenues.
→Branded generics and trade generic margins expected to improve gradually, augmenting revenue growth.
→Overall, growth is linked to sustaining market share, improving product mix, and expanding in regulated markets like Europe.

Margin guidance

→CDMO business volume growth expected at 4-5% in near term, targeting overall revenue growth of 12-13%.
→European contract (EUR 200 million over duration) to commence commercial supply in 2027, spreading revenues until 2032, providing significant growth.
→API business is undergoing rationalization; breakeven expected in 1 to 2 years with focus on high-margin, diversified products and regulated market exports.
→Branded generics and Unosource expected to deliver higher EBITDA margins (18-20%) versus overall CDMO segment (~15.4%).
→R&D investments continue, INR 94 crores in 9 months FY25 aimed at driving new product approvals (17 DCGI approvals FY25 so far).
→Overall, business should see similar revenues and EBITDA to current performance in the short term, with growth accelerated by new contracts and product mix improvements over next 1-3 years.
→Company targets to sustain and grow earnings through volume growth, better product mix, and greater regulatory approvals.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any plans for new fundraising through debt or equity in the near future.
→The company’s cash flow and free cash flow have improved significantly, with free cash flow turning positive in Q3 FY25.
→Current debt stands at INR 322 crores, down from pre-IPO levels.
→The company continues to invest in capex, mainly through internal cash flows, with planned capex of INR 175-200 crores annually for the next two years.
→No explicit mention was made about raising fresh debt or equity for funding these investments.
→Overall, the focus appears on optimizing existing resources and cash flows rather than raising new capital through fundraising.

Order book

→The company has visibility on its order book for the next 60 days (Q4 FY25) and expects decent volume growth in this quarter.
→New contracts discussed earlier are expected to commercialize starting calendar year 2027 (likely Q4 2027 or Q1 next fiscal).
→The recently signed European contract worth EUR 200 million is expected to commence revenues in CY 2027 and will be spread evenly across years.
→Management expressed confidence in securing more contracts in Europe over the next 2 to 3 years, following the successful commencement of the first contract.
→Current order execution for the next six months is primarily reflected in Q4 FY25 with encouraging volume growth envisaged, though details for the entire next fiscal are not disclosed.

Capex plans

→incurred capex of INR 191 crores in 9 months of FY '25, largely in the CDMO vertical
→planned capex of INR 175-200 crores annually over next 2 years to commission new plants and production lines
→INR 32 crores capex over next 2 quarters to upgrade and improve R&D capabilities, focusing on regulated markets and niche dosage forms
→expanding and increasing manufacturing capabilities for nasal sprays, eye drops, bi-layered tablets, ampoules, FFS small volume parenterals
→plans to expand into large volume parenterals, dry powder injectable, and lyophilized vials soon
→expanding/upgrading Mumbai R&D facility, moving to owned property to enhance product development and customer engagement

How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs & Pharmaceuticals Ltd

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Akums Drugs & Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio